Oral Immunotherapy for Egg Allergy: 94% Desensitization in Toddlers

ByParent Science Space Editorial
🟢
Peer-Reviewed Research

Oral Immunotherapy for Egg Allergy: 94% Desensitization Rate in Toddlers Under Two

A 2026 study from researchers in Spain reports that 29 out of 31 children under two years old with egg allergy achieved desensitization after six months of oral immunotherapy. This 93.5% success rate sharply contrasts with a historical control group where 100% of children remained allergic. For families managing a child’s food allergy, this finding points toward a potential shift from passive avoidance to an active treatment strategy.

What Is Oral Immunotherapy for Food Allergy?

Oral immunotherapy, or OIT, is a medical treatment designed to reduce a person’s allergic sensitivity to a specific food. Unlike an avoidance diet, which aims to prevent any exposure, OIT carefully introduces the allergenic food in precise, gradually increasing amounts under medical supervision.

The Mechanics of Desensitization

The goal is not a cure, but a state of desensitization. Desensitization means a child can safely consume a certain amount of the food—like egg in a baked good or a serving of scrambled eggs—without an allergic reaction. This process works by modulating the immune system’s response. As detailed in the Spanish study, successful OIT leads to measurable immunological changes: decreases in allergen-specific IgE antibodies and increases in protective IgG4 antibodies. Essentially, OIT trains the immune system to tolerate the food rather than attack it.

Why Early Intervention Matters: The Case for Starting Young

Egg allergy is one of the most common food allergies in early childhood. Traditional management relies on strict elimination, which carries its own burdens. Avoidance diets can complicate nutrition, increase family stress, and limit a child’s social activities. More critically, accidental exposures remain a constant risk.

Safety and Efficacy in the Youngest Patients

The study by Carrión Sari and colleagues specifically tested OIT in children younger than two, an age group with limited controlled research. Their prospective study assigned 31 infants and toddlers to OIT using pasteurized liquid egg white, building to a maximum dose of 30 mL. Twelve similar children managed with avoidance served as a historical control for comparison.

The six-month results were stark. While none of the control group children outgrew their allergy naturally, 93.5% of the OIT group could ingest egg without reaction. The safety profile was also notable. Most children in the OIT group (77.4%) experienced mild, manageable reactions during the dose-building phase, such as skin rashes or tummy upset. None required an intramuscular epinephrine injection. Conversely, over the same period, half of the children in the avoidance group experienced anaphylaxis from accidental exposure.

These findings suggest that for appropriately selected infants, early OIT may not only be effective but could potentially reduce the overall burden of severe allergic reactions compared to the standard practice of avoidance.

The Science Behind the Results: Tracking Immune System Changes

The Spanish team didn’t just track reactions; they measured precise biomarkers to understand how OIT alters the immune system. These objective measures strengthen the evidence for OIT’s biological effect.

Shifts in Antibody Profiles

The study tracked serum-specific IgE (sIgE), the antibody responsible for triggering allergic symptoms. Levels of sIgE dropped significantly in the OIT group. Simultaneously, levels of specific IgG4 (sIgG4), an antibody thought to play a protective, blocking role, increased. The ratio of sIgE to total IgE also fell, another indicator of a reduced allergic state. These changes correlate directly with the clinical outcome of being able to eat egg safely.

Reduced Skin Reactivity

Skin prick test (SPT) wheal diameters, which measure immediate allergic reactivity in the skin, also decreased substantially in children undergoing OIT. A smaller wheal indicates a less reactive immune system, providing a tangible, in-office measure of treatment progress.

Practical Applications and Considerations for Families

While the data is promising, oral immunotherapy is a serious medical protocol, not a home experiment. It requires a structured, supervised approach.

Who Is a Candidate?

OIT is typically considered for children with a confirmed, IgE-mediated food allergy. The decision to proceed involves a detailed assessment by a pediatric allergist. Factors include the child’s age, allergy history, severity of past reactions, and family readiness for the commitment. This study specifically supports its consideration for children under two with egg allergy.

What Does the Process Involve?

The treatment has distinct phases. It begins with a supervised initial dose escalation in a clinical setting equipped to manage reactions. This is followed by a build-up phase, where daily doses are gradually increased, often with some doses given at home after careful instruction. Finally, a maintenance phase is reached, where the child consumes a consistent target dose of the food every day to maintain desensitization. The entire process demands strict daily adherence and regular follow-up appointments.

Acknowledging Limitations and Risks

Oral immunotherapy is not without challenges. As the study shows, most children experience some adverse reactions during the build-up phase, though they are typically mild. There is also a commitment to daily dosing, which can be difficult to maintain. Furthermore, desensitization is often temporary; if daily maintenance doses are stopped, the allergy may return. This treatment should only be conducted under the guidance of an allergy specialist who can manage risks and tailor the protocol to the individual child.

How This Research Fits into the Broader Allergy Landscape

This study adds to a growing body of evidence that challenges the once-universal recommendation of strict, indefinite avoidance for food allergies. Active treatment through OIT is becoming a more standard option for certain allergens, like peanut and egg. The exceptional desensitization rate in such young children highlights a potential “window of opportunity” in early immune development. Early intervention might lead to more robust and lasting tolerance, though long-term follow-up studies are needed to confirm this. For related insights on early childhood nutrition and health, see our guide on Breastfeeding Support, Infant Health & Development.

Frequently Asked Questions

Is oral immunotherapy a cure for my child’s egg allergy?

No, OIT is not considered a cure. It induces a state of desensitization, meaning your child can safely eat egg while on daily maintenance therapy. If the daily doses stop, the allergy and risk of reaction are likely to return.

How do I know if my toddler is a good candidate for early OIT?

Only a board-certified pediatric allergist can determine candidacy after a thorough evaluation. This includes confirming the IgE-mediated allergy with testing and reviewing your child’s medical history. The study specifically involved children under two with diagnosed egg allergy.

Are the side effects during OIT treatment dangerous?

Most reactions are mild, like skin redness or stomach discomfort, and manageable. However, the risk of a more severe reaction exists, which is why treatment starts in a medical clinic. In the cited study, no child required epinephrine for a reaction during supervised OIT dosing.

If OIT works for egg, can it work for other food allergies?

Yes, OIT protocols are being studied and used for several common food allergies, including peanut, milk, and tree nuts. The principles are similar, but the specific food, dosing, and protocols are tailored to each allergen and individual.

💊 Popular children’s supplements

Available on iHerb (ships to 180+ countries):

Kids Multi ↗
Kids DHA ↗
Kids Vitamin D3 ↗

Affiliate disclosure: we may earn a small commission at no extra cost to you.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42353980/
https://pubmed.ncbi.nlm.nih.gov/42341804/
https://pubmed.ncbi.nlm.nih.gov/42303180/

Key Takeaways

Similar Posts